Familial bladder cancer and the related genes

Current Opinion in Urology

Volumn 21, Issue 5, 2011, Pages 386-392

  Hemminki, Kari ^a,b   Bermejo, Justo L ^c   Ji, Jianguang ^b   Kumar, Rajiv ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Familial risk; familial survival; spouse correlation; susceptibility genes

Indexed keywords

GLUTATHIONE TRANSFERASE M1;

BLADDER CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; ENVIRONMENTAL FACTOR; EYE CANCER; FAMILIAL CANCER; FAMILY; GENE IDENTIFICATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; KIDNEY CANCER; LARYNX CANCER; LEUKEMIA; LUNG CANCER; MELANOMA; NULL ALLELE; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SMOKING; STOMACH CANCER; THYROID CANCER;

ARYLAMINE N-ACETYLTRANSFERASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HUMANS; INCIDENCE; MALE; MULTIGENE FAMILY; SWEDEN; URINARY BLADDER NEOPLASMS;

EID: 80051797196     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32834958ff     Document Type: Review

References (29)

1. Centre for Epidemiology. Cancer incidence in Sweden 2005. Stockholm: the National Board of Health and Welfare; 2007.
2. Engholm G, Ferlay J, Christensen N, et al. NORDCAN: cancer incidence, mortality, prevalence and prediction in the Nordic countries, Version 3.7. Association of the Nordic Cancer Registries, Danish Cancer Society; 2010. http://www.ancr.nu.
3. Mousavi SM, Sundquist J, Hemminki K. Risk of transitional-cell carcinoma of the bladder in first-and second-generation immigrants to Sweden. Eur J Cancer Prev 2010;19:275-279.
4. Storm HH, Kejs AM, Engholm G, et al. Trends in the overall survival of cancer patients diagnosed 1964-2003 in the Nordic countries followed up to the end of 2006: the importance of case-mix. ActaOncol 2010;49:713-724. This study provides most up-to-date survival figures from the Nordic countries.
5. Mueller CM, Caporaso N, Greene MH. Familial and genetic risk of transitional cell carcinoma of the urinary tract. Urol Oncol 2008;26:451-464.
6. Kiemeney L. Hereditary bladder cancer. Scand J Urol Nephrol Suppl 2008;218:110-115.
7. Hemminki K, Ji J, Brandt A, et al. The Swedish Family-Cancer Database 2009: prospects for histology-specific and immigrant studies. Int J Cancer 2010;126:2259-2267.
8. Bermejo JL, Sundquist J, Hemminki K. Sex-specific familial risks of urinary bladder cancer and associated neoplasms in Sweden. Int J Cancer 2009;124:2166-2171.
9. Hemminki K, Sundquist J, Lorenzo Bermejo J. Familial risks for cancer as the basis for evidence-based clinical referral and counseling. Oncologist 2008;13:239-247. (Pubitemid 351679899)
10. Hemminki K, Sundquist J, Brandt A. Familial mortality and familial incidence in cancer. J Clin Oncol 2011;29:712-718.
11. Ji J, Forsti A, Sundquist J, et al. Survival in bladder and renal cell cancers is familial. J Am Soc Nephrol 2008;19:985-991.
12. Andrew AS, Gui J, Sanderson AC, et al. Bladder cancer SNP panel predicts susceptibility and survival. Hum Genet 2009;125:527-539.
13. Grotenhuis AJ, Vermeulen SH, Kiemeney LA. Germline genetic markers for urinary bladder cancer risk, prognosis and treatment response. Future Oncol. 2010;6:1433-60.
14. Hemminki K, Lorenzo Bermejo J, Försti A. The balance between heritable and environmental aetiology of human disease. Nat Rev Genet 2006;7:958-965. (Pubitemid 44871399)
15. Weires M, Bermejo JL, Sundquist J, Hemminki K. Clustering of concordant and discordant cancer types in Swedish couples is rare. Eur J Cancer 2011;47:98-106.
16. van der Post RS, Kiemeney LA, Ligtenberg MJ, et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 2010;47:464-470.
17. Marees T, Moll AC, Imhof SM, et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 2008;100:1771-1779.
18. Zhang R, Xu G, Chen W, Zhang W. Genetic polymorphisms of glutathione Stransferase M1 and bladder cancer risk: a meta-analysis of 26 studies. Mol Biol Rep 2011;38:2491-2497.
19. Guey LT, Garcia-Closas M, Murta-Nascimento C, et al. Genetic susceptibility to distinct bladder cancer subphenotypes. Eur Urol 2010;57:283-292.
20. Moore LE, Baris DR, Figueroa JD, et al. GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis. Carcinogenesis 2011;32:182-189.
21. Stern MC, Lin J, Figueroa JD, et al. Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer. Cancer Res 2009;69:6857-6864.
22. Vineis P, Manuguerra M, Kavvoura FK, et al. A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility. J Natl Cancer Inst 2009;101:24-36.
23. Chen M, Hildebrandt MA, Clague J, et al. Genetic variations in the sonic hedgehog pathway affect clinical outcomes in nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) 2010;3:1235-1245.
24. Garcia-Closas M, Malats N, Real FX, et al. Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet 2007;3:e29.
25. Chen M, Gu J, Delclos GL, Eearcia-Closas M, Chatterjee N, et al. A multistage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 2010;42:978-984. Largest multistage genome wide association study (GWAS) that besides validating discovered by previousGWAS also identified new loci associated with bladder cancer and also validated association with GSTM1 null-type and slow NAT2 acetylation.
26. Kiemeney LA, Thorlacius S, Sulem P, et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 2008;40:1307-1312.
27. Kiemeney LA, Sulem P, Besenbacher S, et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 2010;42:415-419.
28. Rafnar T, Sulem P, Stacey SN, et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 2009;41:221-227.
29. Wu X, Ye Y, Kiemeney LA, et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 2009;41:991-995.